Pulmonary toxicities from targeted therapies: a review (Q37955066)

25 August 2017

title

Pulmonary toxicities from targeted therapies: a review (English)

1 reference

25 August 2017

Nicholas A Barber

1

1 reference

25 August 2017

Apar Kishor Ganti

series ordinal

2

1 reference

25 August 2017

publication date

11 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

6

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

235-243

1 reference

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

FDA drug approval summary: erlotinib (Tarceva) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Pulmonary toxicity from novel antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Recurrent gefitinib-induced interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Management and preparedness for infusion and hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Cetuximab-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Interstitial pneumonitis during imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

The von Hippel-Lindau tumor suppressor gene and kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Tacrolimus-induced lung injury in a rheumatoid arthritis patient with interstitial pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Diffuse alveolar hemorrhage induced by everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Recall pneumonitis during systemic treatment with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Interstitial pneumonitis related to rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Fatal interstitial pneumonitis related to rituximab-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Rituximab-induced lung disease: A systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Oropharyngeal cancer, human papilloma virus, and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Diffuse alveolar hemorrhage following alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Thalidomide may induce interstitial pneumonia preferentially in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Thalidomide-induced organizing pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0199-0

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

21 January 2018

1 reference

12 December 2020

The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis

1 reference

12 December 2020

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

12 December 2020

1 reference

12 December 2020

Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis

1 reference

12 December 2020

Pulmonary Toxicity Associated With Erlotinib

1 reference

12 December 2020

Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP)

1 reference

12 December 2020

Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia

1 reference

12 December 2020

Rituximab-induced acute pulmonary fibrosis

1 reference

12 December 2020

10.1007/S11523-011-0199-0

Identifiers

DOI

1 reference

25 August 2017

1 reference